The FDA published a final order codifying software-aided adjunctive diagnostic devices for physician assessment of suspicious skin lesions as Class II devices subject to special controls under 21 CFR 878.1830. The order became effective October 30, 2026, but the underlying classification had already been applicable since January 12, 2024, following the De Novo authorization of DermaSensor. The device category is intended to provide supplementary information after a suspicious lesion has been identified, not to provide standalone screening or a definitive cancer diagnosis. The codification establishes the regulatory framework for the device category; it is not a newly granted marketing authorization for DermaSensor.
Justia Regulations+2
Sources: Federal Register order, October 30 · FDA De Novo record DEN230008
Why it matters strategically
A defined Class II device category can create a more predictable regulatory pathway for subsequent manufacturers seeking clearance for substantially equivalent devices.
However, the opportunity is limited by intended use, clinical performance requirements, software validation, and the need to demonstrate substantial equivalence to an appropriate predicate.
A lower device classification does not eliminate the need for clinical and technical evidence.
